Flow-Mediated Dilatation in the Assessment of Coronary Heart Disease: A Meta-Analysis

Xiaoyong Xiao1, Xian Li2, Xiaohua Xiao3

  • 1Department of Emergency, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518035, China.

Insights

This meta-analysis reveals that patients with coronary heart disease (CHD) exhibit significantly lower flow-mediated dilatation (FMD) compared to controls. Lower FMD is a key indicator of endothelial dysfunction in CHD patients.

Area of Science:

  • Cardiovascular Research
  • Vascular Biology
  • Medical Diagnostics

Background:

  • Endothelial dysfunction is linked to increased coronary heart disease (CHD) morbidity and mortality.
  • Flow-mediated dilatation (FMD) is a primary noninvasive method for assessing vascular endothelial function.

Purpose of the Study:

  • To conduct a meta-analysis investigating the association between FMD and CHD.
  • To determine if FMD levels differ significantly between individuals with and without CHD.

Main Methods:

  • Systematic search of PubMed, Web of Science, Scopus, and Embase databases.
  • Meta-analysis of 9 studies involving 943 participants (534 CHD patients, 409 controls) using Stata 14.
  • Standardized Mean Difference (SMD) calculated for FMD levels with 95% Confidence Intervals (CI); heterogeneity assessed using I² statistics.

Main Results:

  • Patients with CHD demonstrated significantly lower FMD compared to control groups (SMD -0.706%; 95% CI: -0.985, -0.427; P=0.001).
  • High statistical heterogeneity was observed across the included studies.
  • Funnel plot analysis indicated potential publication bias, though sensitivity analyses found no single influential study.

Conclusions:

  • This meta-analysis provides robust evidence that reduced FMD is significantly associated with coronary heart disease.
  • FMD serves as a critical indicator of endothelial dysfunction and a potential hallmark in the context of CHD.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
23
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
21
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
24
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
46
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
25
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
31